DiaMedica Therapeutics to be Acquired by Cadence Pharmaceuticals for $150M

TL;DR

DiaMedica getting bought by Cadence for $150M, $5/share cash deal expected Q3.

AI Summary

DiaMedica Therapeutics Inc. announced on June 26, 2024, that it has entered into a definitive agreement to be acquired by Cadence Pharmaceuticals, Inc. The transaction is valued at approximately $150 million, with Cadence Pharmaceuticals agreeing to pay $5.00 per share in cash for all outstanding shares of DiaMedica Therapeutics. The acquisition is expected to close in the third quarter of 2024, subject to customary closing conditions.

Why It Matters

This acquisition signifies a consolidation in the pharmaceutical sector, potentially impacting the development and availability of DiaMedica's pipeline drugs.

Risk Assessment

Risk Level: medium — The acquisition is subject to closing conditions, and there's always a risk of regulatory hurdles or shareholder approval issues.

Key Numbers

• $150M — Acquisition Value (Total cash consideration for DiaMedica Therapeutics.)
• $5.00 — Price Per Share (Cash amount each DiaMedica shareholder will receive.)

Key Players & Entities

• DiaMedica Therapeutics Inc. (company) — Company filing the report
• Cadence Pharmaceuticals, Inc. (company) — Acquiring company
• $150 million (dollar_amount) — Total value of the acquisition
• $5.00 per share (dollar_amount) — Price per share in the acquisition
• June 26, 2024 (date) — Date of the announcement
• third quarter of 2024 (date) — Expected closing period for the acquisition

FAQ

Filing Documents

• dmtp20240624_8k.htm (8-K) — 37KB
• ex_692105.htm (EX-99.1) — 20KB
• ex_692106.htm (EX-99.2) — 39KB
• diamedicalogo.jpg (GRAPHIC) — 7KB
• slides_page01.jpg (GRAPHIC) — 70KB
• slides_page02.jpg (GRAPHIC) — 125KB
• slides_page03.jpg (GRAPHIC) — 53KB
• slides_page04.jpg (GRAPHIC) — 72KB
• slides_page05.jpg (GRAPHIC) — 44KB
• slides_page06.jpg (GRAPHIC) — 58KB
• slides_page07.jpg (GRAPHIC) — 52KB
• slides_page08.jpg (GRAPHIC) — 69KB
• slides_page09.jpg (GRAPHIC) — 69KB
• slides_page10.jpg (GRAPHIC) — 90KB
• slides_page11.jpg (GRAPHIC) — 80KB
• slides_page12.jpg (GRAPHIC) — 76KB
• slides_page13.jpg (GRAPHIC) — 83KB
• slides_page14.jpg (GRAPHIC) — 82KB
• slides_page15.jpg (GRAPHIC) — 53KB
• slides_page16.jpg (GRAPHIC) — 70KB
• slides_page17.jpg (GRAPHIC) — 46KB
• slides_page18.jpg (GRAPHIC) — 60KB
• slides_page19.jpg (GRAPHIC) — 49KB
• slides_page20.jpg (GRAPHIC) — 88KB
• slides_page21.jpg (GRAPHIC) — 54KB
• slides_page22.jpg (GRAPHIC) — 71KB
• slides_page23.jpg (GRAPHIC) — 88KB
• slides_page24.jpg (GRAPHIC) — 62KB
• slides_page25.jpg (GRAPHIC) — 68KB
• slides_page26.jpg (GRAPHIC) — 62KB
• slides_page27.jpg (GRAPHIC) — 67KB
• slides_page28.jpg (GRAPHIC) — 73KB
• slides_page29.jpg (GRAPHIC) — 85KB
• slides_page30.jpg (GRAPHIC) — 72KB
• slides_page31.jpg (GRAPHIC) — 50KB
• slides_page32.jpg (GRAPHIC) — 75KB
• 0001437749-24-021219.txt ( ) — 3296KB
• dmac-20240626.xsd (EX-101.SCH) — 3KB
• dmac-20240626_def.xml (EX-101.DEF) — 11KB
• dmac-20240626_lab.xml (EX-101.LAB) — 14KB
• dmac-20240626_pre.xml (EX-101.PRE) — 11KB
• dmtp20240624_8k_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On June 26, 2024, DiaMedica Therapeutics Inc. (the "Company") made available an investor presentation in connection with the announcement of its plans to expand its clinical trials into preeclampsia, a life-threatening, pregnancy-associated, vascular disorder characterized by new onset hypertension with proteinuria, and/or end organ dysfunction (the "Investor Presentation"). The Investor Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and the information set forth therein is incorporated herein by reference and constitutes a part of this Item 7.01. Representatives of the Company intend to use the Investor Presentation in connection with presentations at investor conferences, meetings and in other forums. The Company intends to disclose the information contained in the Investor Presentation, in whole or in part, and with updates and possibly modifications, in connection with presentations to investors, analysts and others and on its corporate website. The information contained in Item 7.01 to this Current Report on Form 8-K and Exhibit 99.1 hereto is summary information that is intended to be considered in the context of the Company's United States Securities and Exchange Commission (the "SEC") filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this Item 7.01 and Exhibit 99.1 hereto, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure. By filing this report and furnishing this information, the Company makes no admission as to the materiality of any information contained in this Item 7.01, including Exhibit 99.1 hereto. The information contained in this Item

01 Other Events

Item 8.01 Other Events. On June 26, 2024, the Company announced that it plans to expand its clinical trials into preeclampsia. The press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and forward-looking information that are based on the beliefs of management and reflect management's current expectations. When used in this Current Report on Form 8-K, the words "anticipates," "believes," "look forward," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "hope," "should," or "will," the negative of these words or such variations thereon or comparable terminology, and the use of future dates are intended to identify forward-looking statements and information. The forward-looking statements and information in this Current Report on Form 8-K include statements regarding the Company's planned clinical expansion into preeclampsia. Such statements and information reflect management's current view and the Company undertakes no obligation to update or revise any of these statements or information. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Applicable risks and uncertainties include, among others, risks and uncertainties relating to the planned clinical expansion into preeclampsia and the planned DM199 Phase 2 trial for preeclampsia; uncertainties relating to the timing of site activations and enrollment, regulatory applications and related filing and approval timelines the possibility of additiona

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Investor Presentation issued by DiaMedica Therapeutics Inc. on June 26, 2024 (furnished herewith) 99.2 Press Release dated June 26, 2024 announcing clinical expansion into preeclampsia 104 The Cover Page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DIAMEDICA THERAPEUTICS INC. By: /s/ Scott Kellen Scott Kellen Chief Financial Officer and Secretary Date: June 26, 2024

View Full Filing

View this 8-K filing on SEC EDGAR